250,000 Shares in Zenas BioPharma, Inc. $ZBIO Acquired by Jennison Associates LLC

Jennison Associates LLC bought a new stake in Zenas BioPharma, Inc. (NASDAQ:ZBIO) in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 250,000 shares of the company’s stock, valued at approximately $4,888,000.

A number of other institutional investors have also modified their holdings of ZBIO. SR One Capital Management LP raised its holdings in shares of Zenas BioPharma by 2.6% in the 4th quarter. SR One Capital Management LP now owns 5,037,854 shares of the company’s stock valued at $182,924,000 after buying an additional 126,315 shares during the period. NEA Management Company LLC boosted its holdings in Zenas BioPharma by 28.9% during the 4th quarter. NEA Management Company LLC now owns 3,523,219 shares of the company’s stock valued at $127,928,000 after acquiring an additional 789,500 shares during the period. Federated Hermes Inc. grew its position in Zenas BioPharma by 45.9% in the 4th quarter. Federated Hermes Inc. now owns 2,715,578 shares of the company’s stock valued at $98,603,000 after acquiring an additional 853,740 shares in the last quarter. Vanguard Group Inc. increased its stake in Zenas BioPharma by 25.0% during the fourth quarter. Vanguard Group Inc. now owns 1,453,065 shares of the company’s stock worth $52,761,000 after purchasing an additional 290,307 shares during the period. Finally, Polar Capital Holdings Plc purchased a new stake in Zenas BioPharma during the fourth quarter worth about $38,402,000.

Zenas BioPharma Price Performance

Zenas BioPharma stock opened at $32.36 on Wednesday. The company has a current ratio of 11.94, a quick ratio of 11.94 and a debt-to-equity ratio of 1.04. The company has a fifty day simple moving average of $22.26 and a 200-day simple moving average of $22.07. The stock has a market cap of $2.04 billion, a P/E ratio of -3.82 and a beta of -0.96. Zenas BioPharma, Inc. has a 12-month low of $13.50 and a 12-month high of $44.60.

Zenas BioPharma (NASDAQ:ZBIO) last posted its earnings results on Wednesday, May 13th. The company reported ($1.46) EPS for the quarter, beating the consensus estimate of ($1.47) by $0.01. During the same period in the previous year, the business posted ($0.80) earnings per share. Equities analysts expect that Zenas BioPharma, Inc. will post -4.47 EPS for the current fiscal year.

Insider Transactions at Zenas BioPharma

In related news, CEO Leon O. Moulder, Jr. purchased 60,000 shares of the company’s stock in a transaction on Monday, May 18th. The shares were bought at an average cost of $16.88 per share, for a total transaction of $1,012,800.00. Following the completion of the purchase, the chief executive officer directly owned 96,928 shares of the company’s stock, valued at approximately $1,636,144.64. This trade represents a 162.48% increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders purchased 120,000 shares of company stock valued at $2,080,000 over the last three months. Corporate insiders own 22.00% of the company’s stock.

Analysts Set New Price Targets

ZBIO has been the subject of several recent research reports. Zacks Research raised shares of Zenas BioPharma from a “strong sell” rating to a “hold” rating in a research note on Friday, May 15th. Wall Street Zen upgraded shares of Zenas BioPharma from a “strong sell” rating to a “sell” rating in a report on Saturday, June 27th. Morgan Stanley raised their price target on shares of Zenas BioPharma from $21.00 to $22.00 and gave the company an “equal weight” rating in a research report on Thursday, May 14th. Citigroup restated a “buy” rating on shares of Zenas BioPharma in a research note on Wednesday, June 3rd. Finally, Weiss Ratings lowered Zenas BioPharma from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, July 9th. Six investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $44.29.

Zenas BioPharma Profile

Zenas BioPharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company’s proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.

Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies.